Michael Gnant

77.9k total citations · 10 hit papers
555 papers, 37.9k citations indexed

About

Michael Gnant is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Gnant has authored 555 papers receiving a total of 37.9k indexed citations (citations by other indexed papers that have themselves been cited), including 349 papers in Oncology, 225 papers in Cancer Research and 188 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Gnant's work include Breast Cancer Treatment Studies (189 papers), Advanced Breast Cancer Therapies (135 papers) and Estrogen and related hormone effects (93 papers). Michael Gnant is often cited by papers focused on Breast Cancer Treatment Studies (189 papers), Advanced Breast Cancer Therapies (135 papers) and Estrogen and related hormone effects (93 papers). Michael Gnant collaborates with scholars based in Austria, United States and Germany. Michael Gnant's co-authors include Nadia Harbeck, R. Jakesz, Eugene Manley, Matthews, Donna Wright, C A Cull, Irene Stratton, R. C. Turner, Honora H. McElroy and David R. Hadden and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Gnant

531 papers receiving 36.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

1998 7.2k citations Michael Gnant et al. profile →
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 6.9k citations Michael Gnant et al. profile →
Breast cancer

2019 2.0k citations Nadia Harbeck, Michael Gnant et al. profile →
Breast cancer

2016 1.7k citations Nadia Harbeck, Michael Gnant profile →
Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.

1991 1.5k citations Michael Gnant et al. PubMed profile →
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

2005 642 citations R. Jakesz, Michael Gnant et al. profile →
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

2019 438 citations Sibylle Loibl, Peter Dubsky et al. Annals of Oncology profile →
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Shinzaburo Noguchi, Kathleen I. Pritchard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Gnant Austria	71	13.1k	10.0k	8.8k	7.8k	7.6k	555	37.9k
Hashem B. El‐Serag United States	123	10.2k 0.8×	8.5k 0.9×	23.3k 2.6×	12.2k 1.6×	3.5k 0.5×	654	69.4k
Elisabeth G.E. de Vries Netherlands	102	24.1k 1.8×	6.4k 0.6×	5.2k 0.6×	14.3k 1.8×	1.5k 0.2×	1.0k	47.8k
Patrick Maisonneuve Italy	108	17.1k 1.3×	10.4k 1.0×	12.2k 1.4×	6.2k 0.8×	1.9k 0.2×	567	41.9k
Scott M. Lippman United States	89	12.8k 1.0×	7.9k 0.8×	4.8k 0.5×	13.5k 1.7×	1.5k 0.2×	528	37.2k
Børge G. Nordestgaard Denmark	120	3.5k 0.3×	8.8k 0.9×	27.1k 3.1×	7.8k 1.0×	18.8k 2.5×	953	65.2k
Charles S. Fuchs United States	125	30.0k 2.3×	8.8k 0.9×	9.1k 1.0×	15.4k 2.0×	2.3k 0.3×	721	58.8k
Susan S. Devesa United States	90	11.5k 0.9×	3.5k 0.4×	7.8k 0.9×	5.4k 0.7×	2.7k 0.4×	205	30.5k
Angela B. Mariotto United States	57	17.2k 1.3×	5.7k 0.6×	4.3k 0.5×	7.5k 1.0×	811 0.1×	149	37.7k
J.W.W. Coebergh Netherlands	87	16.3k 1.2×	4.5k 0.4×	5.3k 0.6×	3.9k 0.5×	1.1k 0.1×	520	30.6k
Nicholas J. Vogelzang United States	89	17.2k 1.3×	6.5k 0.6×	10.1k 1.1×	8.4k 1.1×	2.2k 0.3×	701	41.8k

Countries citing papers authored by Michael Gnant

Since Specialization

Citations

This map shows the geographic impact of Michael Gnant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gnant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gnant more than expected).

Fields of papers citing papers by Michael Gnant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gnant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gnant. The network helps show where Michael Gnant may publish in the future.

Co-authorship network of co-authors of Michael Gnant

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gnant. A scholar is included among the top collaborators of Michael Gnant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gnant. Michael Gnant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agostinetto, Elisa, Georg Pfeiler, Dominik Hlauschek, et al.. (2025). Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). ESMO Open. 10(1). 104096–104096. 1 indexed citations

Wimmer, Kerstin, Dominik Hlauschek, Marija Balić, et al.. (2024). Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?. Breast Cancer Research and Treatment. 205(2). 227–239. 1 indexed citations

Filipits, Martin, Margaretha Rudas, Christian F. Singer, et al.. (2021). The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. Clinical Cancer Research. 27(21). 5931–5938. 1 indexed citations

Filipits, Martin, Margaretha Rudas, Christian F. Singer, et al.. (2021). ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. ESMO Open. 6(4). 100228–100228. 16 indexed citations

Papakonstantinou, Andri, Alexios Matikas, Per Malmström, et al.. (2019). Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer. 126(6). 1175–1182. 14 indexed citations

Bergen, Elisabeth, Anna S. Berghoff, Margaretha Rudas, et al.. (2019). Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. Clinical Cancer Research. 25(9). 2737–2744. 33 indexed citations

Filipits, Martin, Urania Dafni, Michael Gnant, et al.. (2018). Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research. 24(13). 3079–3086. 15 indexed citations

Singer, Christian F., Yen Y. Tan, Florian Fitzal, et al.. (2017). Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clinical Cancer Research. 23(14). 3676–3683. 32 indexed citations

Bergen, Elisabeth, Anna S. Berghoff, Peter Dubsky, et al.. (2016). Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment. 157(1). 91–99. 17 indexed citations

10.

Steger, Guenther G., Michael Gnant, & Rupert Bartsch. (2015). Palbociclib for the treatment of postmenopausal breast cancer – an update. Expert Opinion on Pharmacotherapy. 17(2). 255–263. 15 indexed citations

11.

Exner, Ruth, Zsuzsanna Bagó-Horváth, Rupert Bartsch, et al.. (2014). The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer. British Journal of Cancer. 111(5). 837–842. 23 indexed citations

12.

Dubsky, Peter, Jan C. Brase, R. Jakesz, et al.. (2013). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. British Journal of Cancer. 109(12). 2959–2964. 235 indexed citations

13.

Gnant, Michael, José Baselga, Hope S. Rugo, et al.. (2013). Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. JNCI Journal of the National Cancer Institute. 105(9). 654–663. 77 indexed citations

14.

Berghoff, Anna S., Zsuzsanna Bagó-Horváth, Peter Dubsky, et al.. (2012). Brain metastases free survival differs between breast cancer subtypes. British Journal of Cancer. 106(3). 440–446. 68 indexed citations

15.

Bartsch, Rupert, Anna S. Berghoff, Ursula Pluschnig, et al.. (2011). Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. British Journal of Cancer. 106(1). 25–31. 60 indexed citations

16.

Gnant, Michael, Walter Schippinger, G. Luschin-Ebengreuth, et al.. (2009). アジュバント内分泌療法へのゾレドロン酸(ZOL)追加はホルモン応答性早期乳房腫瘍(HREBC)の閉経前女性の無病生存(DF)及び非再発生存(RFS)を改善する:オーストリア乳房腫瘍及び結腸直腸腫瘍研究グループ12(ABCSG-12)試験の多変量解析. Annals of Oncology. 20. 30. 1 indexed citations

17.

Dowsett, Mitch, Jack Cuzick, J. N. Ingle, et al.. (2009). Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology. 28(3). 509–518. 581 indexed citations breakdown →

18.

Schindl, Monika, Sebastian F. Schoppmann, Hellmut Samonigg, et al.. (2002). Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.. PubMed. 8(6). 1831–7. 332 indexed citations

19.

Rudas, M., et al.. (1997). p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. European Journal of Cancer. 33(1). 39–44. 63 indexed citations

20.

Kandioler, Daniela, Gerhard Dekan, Adelheid End, et al.. (1996). Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. Journal of Thoracic and Cardiovascular Surgery. 111(4). 827–832. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact